Business & Finance
Deciphera Pharmaceuticals' net loss narrows to USD21.5m in Q2 2019
5 August 2019 -

Biopharmaceutical company Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) on Friday declared a net loss of USD21.5m (USD0.56 per share) for the second quarter ended 30 June 2019.

This marks a slight improvement in earnings when compared with a net loss of USD21.7m (USD0.65 per share) for the same period in 2018.

Revenues of USD25.0m were collected for the second quarter of 2019. It recognized license revenue of USD20.0m for an upfront fee and USD5.0m for a development milestone related to the INTRIGUE study. Revenues were nil in the second quarter 2018.

Research and development expenses of USD34.8m were recorded for the second quarter of 2019, a rise versus R&D of USD18.0m for the same period in 2018, which was primarily due to the INTRIGUE Phase 3 clinical study in second-line GIST and to the INVICTUS Phase 3 clinical study in fourth-line and fourth-line plus GIST.